Micardis: Effective Blood Pressure Control for Cardiovascular Health
Micardis
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.73 | $52.00 (0%) | 🛒 Add to cart |
| 60 | $1.33 | $104.00 $80.00 (23%) | 🛒 Add to cart |
| 90 | $1.19 | $156.00 $107.00 (31%) | 🛒 Add to cart |
| 120 | $1.12 | $208.00 $134.00 (36%) | 🛒 Add to cart |
| 180 | $1.05 | $312.00 $189.00 (39%) | 🛒 Add to cart |
| 270 | $1.01 | $468.00 $273.00 (42%) | 🛒 Add to cart |
| 360 |
$0.99
Best per pill
|
$624.00 $356.00 (43%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.47 | $74.00 (0%) | 🛒 Add to cart |
| 60 | $1.95 | $148.00 $117.00 (21%) | 🛒 Add to cart |
| 90 | $1.79 | $222.00 $161.00 (27%) | 🛒 Add to cart |
| 120 | $1.69 | $296.00 $203.00 (31%) | 🛒 Add to cart |
| 180 | $1.61 | $444.00 $290.00 (35%) | 🛒 Add to cart |
| 270 | $1.55 | $666.00 $419.00 (37%) | 🛒 Add to cart |
| 360 |
$1.52
Best per pill
|
$888.00 $548.00 (38%) | 🛒 Add to cart |
|
Synonyms
|
|||
Micardis (telmisartan) is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adults. It may be used alone or in combination with other antihypertensive agents. By selectively blocking the binding of angiotensin II to the AT1 receptor, Micardis inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure. This mechanism offers a well-tolerated, once-daily option for long-term management of essential hypertension, contributing to reduced cardiovascular risk when blood pressure is adequately controlled.
Features
- Active ingredient: Telmisartan
- Drug class: Angiotensin II receptor blocker (ARB)
- Available in tablet strengths: 20 mg, 40 mg, 80 mg
- Once-daily dosing regimen
- Bioavailability: Approximately 42%
- Half-life: Approximately 24 hours
- Protein binding: >99.5%
- Primary excretion route: Feces (97%)
- FDA-approved for hypertension treatment
Benefits
- Provides sustained 24-hour blood pressure control with single daily dosing
- Demonstrates excellent tolerability profile with low incidence of side effects
- Shows neutral metabolic effects with no significant impact on glucose, lipids, or uric acid
- Offers renal protective properties through selective RAAS inhibition
- May provide cardiovascular risk reduction beyond blood pressure lowering
- Maintains consistent antihypertensive efficacy throughout day and night
Common use
Micardis is primarily prescribed for the management of essential hypertension in adult patients. It may be used as monotherapy or in combination with other antihypertensive medications such as thiazide diuretics or calcium channel blockers when additional blood pressure control is required. The medication is particularly suitable for patients who require once-daily dosing convenience and those who may benefit from its metabolic neutrality. Clinical studies have demonstrated its effectiveness across various patient populations, including those with isolated systolic hypertension and patients with type 2 diabetes.
Dosage and direction
The recommended initial dose of Micardis is 40 mg once daily. Dosage may be increased to 80 mg once daily based on blood pressure response. For patients with possible depletion of intravascular volume, consider initiating therapy with 20 mg once daily. The tablets may be taken with or without food, preferably at the same time each day to maintain consistent plasma concentrations. Blood pressure response typically occurs within 2 weeks, with maximal effects achieved within 4 weeks. For patients requiring additional blood pressure control, combination therapy with hydrochlorothiazide (Micardis HCT) is available.
Precautions
Monitor renal function and electrolytes in patients with impaired renal function, as changes in renal function may occur. Use with caution in patients with hepatic impairment, as telmisartan is extensively metabolized in the liver. Avoid use in patients with biliary obstructive disorders. Monitor for hypotension in volume-depleted patients or those receiving concurrent diuretics. Periodic assessment of serum potassium is recommended, especially in patients with renal impairment or diabetes. Exercise caution in patients with severe congestive heart failure. Not recommended during pregnancy due to potential fetal harm.
Contraindications
Hypersensitivity to telmisartan or any component of the formulation. Concomitant use with aliskiren in patients with diabetes. Second and third trimester of pregnancy due to risk of fetal injury and death. Severe hepatic impairment. Biliary obstructive disorders. Concomitant use with ACE inhibitors in patients with diabetic nephropathy.
Possible side effects
Common adverse reactions (≥1% and greater than placebo) include: upper respiratory infection, back pain, sinusitis, diarrhea, and pharyngitis. Less common side effects may include: dizziness, headache, fatigue, abdominal pain, nausea, hypotension, hyperkalemia, and increased serum creatinine. Rare but serious adverse effects include: angioedema, renal impairment, orthostatic hypotension, and elevated liver enzymes. Most side effects are mild to moderate in severity and often transient.
Drug interaction
Concomitant use with other RAAS agents (ACE inhibitors, aliskiren) may increase risk of hypotension, hyperkalemia, and renal impairment. NSAIDs may reduce antihypertensive effect and increase risk of renal impairment. Lithium levels may increase when used concurrently. Digoxin concentrations may be increased. Potassium-sparing diuretics or potassium supplements may increase risk of hyperkalemia. Warfarin may experience decreased peak plasma concentration. Alcohol, barbiturates, or narcotics may potentiate hypotensive effect.
Missed dose
If a dose is missed, take it as soon as remembered on the same day. If the missed dose is not remembered until the next day, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Maintain consistent dosing intervals to ensure optimal blood pressure control. Patients should be advised to establish a routine for medication administration to minimize missed doses.
Overdose
Symptoms of overdose may include hypotension, tachycardia, bradycardia, dizziness, and possible renal failure. Management should include supportive measures with close monitoring of vital signs and electrolyte balance. Gastric lavage may be considered if ingestion occurred recently. Intravenous normal saline may be administered for hypotension. Hemodialysis is not effective due to high protein binding. Symptomatic treatment should be provided based on clinical presentation.
Storage
Store at room temperature between 15-30°C (59-86°F). Keep in original container with lid tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not use if tablets appear discolored or show signs of deterioration. Properly discard any unused medication after expiration date. Do not flush medications down the toilet or pour into drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any medication regimen. Individual patient responses may vary. The prescribing physician should consider the complete prescribing information before initiating therapy. Not all possible uses, directions, precautions, warnings, or side effects are included here.
Reviews
Clinical trials demonstrate Micardis provides effective 24-hour blood pressure control with excellent tolerability. The ONTARGET study showed telmisartan was non-inferior to ramipril in high-risk cardiovascular patients. Multiple meta-analyses confirm the consistent antihypertensive efficacy across diverse patient populations. Real-world evidence supports its long-term safety profile and patient adherence due to once-daily dosing. Healthcare providers report satisfactory blood pressure control in approximately 70-80% of patients with monotherapy.